Loading organizations...
Key people at Limerick BioPharma.
Limerick BioPharma develops compounds mitigating drug-induced toxicities, enhancing crucial therapeutics. Its lead candidate, LIM-0705, targets severe side effects of immunosuppressive drugs like tacrolimus, vital for transplant patients. LIM-0705 activates specific ABC transporters, selectively removing tacrolimus from vulnerable cells. This preserves immunosuppressive activity, improving patient safety and tolerability.
Founded in 2004 by Wendye R Robbins and Thomas Glaze, the company addressed critical drug-induced toxicities often limiting efficacy and patient compliance with life-saving medications. Robbins and Glaze sought therapies protecting healthy tissues from adverse effects, improving outcomes without compromising primary therapeutic action.
Limerick BioPharma targets organ transplant recipients, often burdened by immunosuppressant reactions. Its vision centers on making crucial, life-sustaining drugs safer and more tolerable. Through focused toxicity mitigation, it strives to extend vital medication's therapeutic window, fostering adherence and successful post-transplant recoveries.
No independent company named Limerick BioPharma appears in available sources; the query likely refers to Lilly Limerick, Eli Lilly's state-of-the-art biotech manufacturing campus in Raheen, Co. Limerick, Ireland, under construction and set to produce drug substances by 2026.[1] This facility builds next-generation biotech medicines, serving global patients with therapies in areas like diabetes, immunology, and oncology, while solving manufacturing challenges for high-demand biologics through advanced platforms in chemical synthesis, peptide synthesis, and biotechnology.[1] Currently employing 260 people and scaling to 450, it forms part of Lilly's €1 billion expansion in Limerick, contributing to Ireland's biopharma hub with over 3,700 Lilly employees across sites.[1][2]
Lilly Limerick operates within a thriving Limerick life sciences ecosystem, alongside giants like Regeneron (1,400 employees producing monoclonal antibodies for EYLEA, Dupixent, and Libtayo) and others such as Cook Medical and Stryker, driving local job growth and innovation in biopharma manufacturing.[2][7]
Lilly's Irish presence began in 1978 with a farm purchase near Kinsale, Co. Cork, evolving into a global active ingredient manufacturing site.[1] The Limerick campus represents a pivotal expansion: announced as a greenfield "Next Generation Biotech" facility, it broke ground recently and is on track for medicine production in 2026, making it Lilly's most advanced manufacturing site.[1] This builds on Lilly's long-term commitment to Ireland, now spanning manufacturing in Limerick and Kinsale, global business services in Cork, and a commercial team focusing on patient needs in key therapeutic areas.[1]
Key figures include Lilly's leadership driving the €1 billion investment, amid Limerick's rise as a biopharma hotspot sparked by multinationals like Regeneron, which launched its first overseas site there in 2014 to support pipeline growth.[2][3][6]
Lilly Limerick rides the global biopharma manufacturing boom, fueled by demand for biologics like monoclonal antibodies and peptides amid aging populations and chronic disease rises.[1][2] Timing aligns with Ireland's life sciences surge—home to top players like Regeneron, J&J, and BMS—bolstered by tax incentives, skilled workforce (e.g., 62 nationalities at Lilly's Cork site), and EU access.[1][4][5][7] Market forces include supply chain resilience post-COVID and Ireland's 25%+ share of Europe's biopharma output, with Limerick's ecosystem fostering spin-outs and SMEs via big-pharma spillovers.[2][7] It influences the landscape by creating 1,200+ jobs (including expansions), elevating Limerick as a "vibrant" hub for health challenges.[2][7]
Lilly Limerick will operationalize in 2026, ramping to full capacity and anchoring Lilly's Irish growth amid pipeline expansions in oncology and immunology.[1] Trends like AI-driven process optimization and personalized medicine will shape it, alongside Ireland's €10B+ life sciences investments.[4][7] Its influence may evolve by spawning local startups and talent pipelines, solidifying Limerick's role in global drug supply—much like Regeneron's 2014 launch catalyzed the cluster—ultimately delivering therapies to millions while boosting Ireland's ecosystem.[2][3][6][7]
Key people at Limerick BioPharma.
